Sorafenib exerts potent inhibitory activity against the EMT phenotype and P-gp-mediated MDR by inhibiting MAPK signaling in HCC [5, 6], whereas the long-term exposure of liver cancer cells to sorafenib has been reported to induce resistance, EMT, increased invasion and risk of rebound growth [14]. The gene discussed is PGP; the disease is liver cancer.